Paper34571995
D-2-Hydroxyglutarate in Glioma Biology.
Chou FJ and 3 others. Cells, 2021. Cited by 60 papers, by iCite.
Cite this record
ConductScience Library. D-2-Hydroxyglutarate in Glioma Biology. Papers, record 34571995. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34571995
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Glioma | Major topic |
| Glutarates | Major topic |
| Isocitrate Dehydrogenase | Major topic |
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | |
| Brain Neoplasms | |
| Carcinogenesis | |
| Cell Transformation, Neoplastic | |
| DNA Methylation | |
| Humans | |
| Hypoxia | |
| Ketoglutaric Acids | |
| Mutation | |
| Signal Transduction |
Source PubMed
References144
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18772396 | An integrated genomic analysis of human glioblastoma multiforme. | Science | 2008 | https://conductscience.org/library/papers/18772396 | PubMed |
| 2 | 28124097 | Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. | Acta Neuropathol | 2017 | https://conductscience.org/library/papers/28124097 | PubMed |
| 3 | 11927290 | HIF-1 and tumor progression: pathophysiology and therapeutics. | Trends Mol Med | 2002 | https://conductscience.org/library/papers/11927290 | PubMed |
| 5 | 20538800 | Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. | Blood | 2010 | https://conductscience.org/library/papers/20538800 | PubMed |
| 6 | 28298040 | Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting. | J Neurosurg | 2018 | https://conductscience.org/library/papers/28298040 | PubMed |
| 7 | 29408410 | The role of mTOR-mediated signaling in the regulation of cellular migration. | Immunol Lett | 2018 | https://conductscience.org/library/papers/29408410 | PubMed |
| 8 | 15003941 | HIFs and tumors--causes and consequences. | Am J Physiol Regul Integr Comp Physiol | 2004 | https://conductscience.org/library/papers/15003941 | PubMed |
| 9 | 29038145 | Oncometabolites: A New Paradigm for Oncology, Metabolism, and the Clinical Laboratory. | Clin Chem | 2017 | https://conductscience.org/library/papers/29038145 | PubMed |
| 10 | 23796461 | Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. | Cancer Discov | 2013 | https://conductscience.org/library/papers/23796461 | PubMed |
| 11 | 30662577 | Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence. | Dis Markers | 2018 | https://conductscience.org/library/papers/30662577 | PubMed |
| 12 | 16362057 | Histone demethylation by a family of JmjC domain-containing proteins. | Nature | 2006 | https://conductscience.org/library/papers/16362057 | PubMed |
| 13 | 31548295 | Blockade of Glutathione Metabolism in IDH1-Mutated Glioma. | Mol Cancer Ther | 2020 | https://conductscience.org/library/papers/31548295 | PubMed |
| 14 | 20472883 | mTOR signaling in glioblastoma: lessons learned from bench to bedside. | Neuro Oncol | 2010 | https://conductscience.org/library/papers/20472883 | PubMed |
| 15 | 19411852 | Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids. | Cell Cycle | 2009 | https://conductscience.org/library/papers/19411852 | PubMed |
| 16 | 19008644 | Regulation of neuronal glutathione synthesis. | J Pharmacol Sci | 2008 | https://conductscience.org/library/papers/19008644 | PubMed |
| 17 | 6787330 | L-2-Hydroxyglutaric aciduria: an inborn error of metabolism? | J Inherit Metab Dis | 1980 | https://conductscience.org/library/papers/6787330 | PubMed |
| 18 | 20399149 | Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. | Cancer Cell | 2010 | https://conductscience.org/library/papers/20399149 | PubMed |
| 19 | 29346478 | Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study. | JAMA Oncol | 2018 | https://conductscience.org/library/papers/29346478 | PubMed |
| 20 | 31888244 | Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31888244 | PubMed |
| 21 | 31004262 | Isocitrate dehydrogenase1 mutation reduces the pericyte coverage of microvessels in astrocytic tumours. | J Neurooncol | 2019 | https://conductscience.org/library/papers/31004262 | PubMed |
Cited by49
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 60 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42950802 | Development of Radioiodinated Tetrahydropyrazolopyridine Inhibitors Targeting mIDH. | J Labelled Comp Radiopharm | 2026 | https://conductscience.org/library/papers/42950802 | PubMed |
| 42849655 | Genome-wide CRISPR screen identifies PKMYT1 inhibition as a synthetic lethal vulnerability in IDH1-mutant glioma. | Cancer Lett | 2026 | https://conductscience.org/library/papers/42849655 | PubMed |
| 42840536 | Cancer metabolism rewiring and chromatin methylation: a vulnerable epi-metabolic link. | Front Epigenet Epigenom | 2025 | https://conductscience.org/library/papers/42840536 | PubMed |
| 42754238 | Redefining care for IDH-mutant low-grade gliomas: Clinical implications of the INDIGO trial and updated guidelines. | Clin Med (Lond) | 2026 | https://conductscience.org/library/papers/42754238 | PubMed |
| 42477897 | Isocitrate Dehydrogenase Mutation Assessment in Human Glioma Using Desorption Electrospray Ionization-Multiple Reaction Monitoring. | Anal Chem | 2026 | https://conductscience.org/library/papers/42477897 | PubMed |
| 42365201 | SMPD3 suppresses oligodendroglioma growth via dual autocrine-paracrine roles. | Commun Biol | 2026 | https://conductscience.org/library/papers/42365201 | PubMed |
| 42344927 | Mitochondria: from powerhouses of cells to hubs in antitumor immunity. | Front Immunol | 2026 | https://conductscience.org/library/papers/42344927 | PubMed |
| 42326329 | Targeting mitochondria as a potential therapeutic strategy against radioresistance in cancer. | Front Oncol | 2026 | https://conductscience.org/library/papers/42326329 | PubMed |
| 42325300 | Shared urinary metabolomic signatures as potential biomarkers for early intestinal Schistosoma infection across multiple species. | Curr Res Parasitol Vector Borne Dis | 2026 | https://conductscience.org/library/papers/42325300 | PubMed |
| 42063150 | Development and validation of a preoperative glycolipid metabolism-based nomogram for predicting postoperative recurrence in primary glioma: a retrospective cohort study. | Lipids Health Dis | 2026 | https://conductscience.org/library/papers/42063150 | PubMed |
| 41665790 | Development and validation of a prognosis model for low-grade gliomas based on metabolic gene risk scoring and immune microenvironment interaction. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41665790 | PubMed |
| 41599746 | Current Pharmacotherapeutic Strategies in Diffuse Gliomas: Focus on Glioblastoma, IDH-Wildtype, and Emerging Targeted Therapies for IDH-Mutant Tumors. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/41599746 | PubMed |
| 41516249 | The TRiC/CCT Complex at the Crossroads of Metabolism and Hypoxia in GBM: Implications for IDH-Dependent Therapeutic Targeting. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41516249 | PubMed |
| 41450919 | Metabolism of glioblastoma: a review of metabolic adaptations and metabolic therapeutic interventions. | Front Oncol | 2025 | https://conductscience.org/library/papers/41450919 | PubMed |
| 41301080 | Bridging Discovery and Treatment: Cancer Biomarker. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41301080 | PubMed |
| 41294748 | Cancer and Aging Biomarkers: Classification, Early Detection Technologies and Emerging Research Trends. | Biosensors (Basel) | 2025 | https://conductscience.org/library/papers/41294748 | PubMed |
| 41211508 | Ambient ionization mass spectrometry in brain cancer diagnosis. | J Mass Spectrom Adv Clin Lab | 2025 | https://conductscience.org/library/papers/41211508 | PubMed |
| 41204377 | EZHIP boosts neuronal-like synaptic gene programs and depresses polyamine metabolism. | Acta Neuropathol Commun | 2025 | https://conductscience.org/library/papers/41204377 | PubMed |
| 40943163 | C. elegans Cytoplasmic Isocitrate Dehydrogenase Neomorphic G98N and R133H Mutants Produce the Oncometabolite 2-Hydroxyglutarate. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40943163 | PubMed |
| 40725110 | The Utility of Metabolomics in Spinal Cord Injury: Opportunities for Biomarker Discovery and Neuroprotection. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40725110 | PubMed |
Genes46
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34571995
GET https://conductscience.org/api/papers/v1/34571995/references?page=2